|Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis|
Under this non-exclusive collaboration agreement, Portola will receive an upfront payment and is eligible to receive additional development and regulatory milestone payments.
"We are pleased to continue our collaboration with
Currently, millions of patients are treated with Factor Xa inhibitors for short-term use or chronic conditions, and the anticoagulant market is expected to continue to grow with the adoption of novel oral anticoagulants. Clinical trial results suggest that, depending on their underlying medical condition, annually between 1 and 4 percent of these patients will experience uncontrolled bleeding, and an additional 1 percent will require emergency surgery.i Currently, there is no antidote or reversal agent approved for use against Factor Xa inhibitors. Leading clinicians have identified, and the
About Andexanet Alfa*
Portola has entered into clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors, while retaining all rights to the program.
Portola has completed and reported data from a Phase 2 proof-of-concept study of andexanet alfa and Eliquis. Results showed that andexanet alfa produces immediate, dose-dependent and well-tolerated reversal of anti-Factor Xa activity. The reversal can be either temporary through the administration of an intravenous bolus or sustained by the addition of an extended infusion. This is critical in covering the multiple clinical scenarios in which a reversal agent would be needed, which could include patients suffering major uncontrolled bleeding from trauma or those needing emergency surgery.
Portola has also reported data from a Phase 2 proof-of-concept study of andexanet alfa and XARELTO® (rivaroxaban).
The Phase 2 studies, which have included more than 80 volunteers, have shown that andexanet alfa is well tolerated, with no thrombotic events, serious adverse events or antibodies to Factor Xa or Factor X observed.
Additional Phase 2 proof-of-concept studies with the direct Factor Xa inhibitors, betrixaban and SavaysaTM (edoxaban), and the indirect Factor Xa inhibitor, enoxaparin, are either planned or ongoing.
Cerdulatinib* (PRT2070) and PRT2607
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Portola's plans for future clinical studies and pursuit of an Accelerated Approval process for andexanet alfa, anticipated growth in the market for anticoagulants, and the potential efficacy, safety and activity of andexanet alfa, betrixaban and cerdulatinib. Risks that contribute to the uncertain nature of the forward-looking statements include: the accuracy of Portola's estimates regarding its ability to initiate and/or complete its clinical trials; the success of Portola's clinical trials and the demonstrated efficacy of Portola's product candidates thereunder; the accuracy of Portola's estimates regarding its expenses and capital requirements; regulatory developments in
*Andexanet alfa and cerdulatinib are proposed International Nonproprietary Names (pINN).
iRivaroxaban ROCKET (3.6% TIMI Major); Apixaban ARISTOTLE (2.1% ISTH Major, 0.96 TIMI Major); Levi, Blood. 2008;111:4471-4476; Circulation. 2012;126:343-348.
iiLu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine. Published online